SJSrinivasan Jayakumar

Srinivasan Jayakumar

*This is an algorithmically generated author record based on publicly available information.

Srinivasan Jayakumar has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of Non-competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-opioid Therapeutic Strategy for Neuropathic Pain

    by Christopher L. Cioffi, Tanmay K. Pati, Irina Lotsaris, Srinivasan Jayakumar, Julian Peiser-Oliver, Gaddam Mahesh, Ryan P. Cantwell Chater, Aravindan Jayaraman, Zachary J. Frangos, Krishna Suleria, et al.

    Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2–/–) mice. To address these challenges, we developed a series of second-generation, conformationally restricted indoline analogues that act as noncompetitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, nonopioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.

  • Bioresponsive MR Imaging Probes for Noninvasive Monitoring of AAV Gene Therapy

    by Jian-Hong Tang, Toloo Taghian, Srinivasan Jayakumar, Giacomo Parigi, Claudio Luchinat, Erin Hall, Heather L. Gray-Edwards, Thomas J. Meade

    Gene therapy has emerged as a powerful approach for treating diverse diseases, including genetic disorders, retinal diseases, and certain cancers. Real-time, noninvasive in vivo tracking of gene expression is essential for evaluating therapeutic efficacy. β-galactosidase (β-gal), a hydrolase encoded by the Escherichia coli lacZ gene or the human GLB1 gene, is widely used as a reporter of gene expression. In humans, β-gal deficiency underlies several fatal neurodegenerative disorders, including GM1 gangliosidosis. Here, we report the development of a β-gal-activated, human serum albumin (HSA)-binding gadolinium(III)-based MR contrast agent for noninvasive assessment of adeno-associated virus (AAV) gene therapy in GM1 gangliosidosis mice. The probe exhibited a gradual increase in MR relaxation rate upon incubation with β-gal in the presence of 4.5% HSA. Following intravenous administration, AAV-treated GM1 mice demonstrated distinct MR signal enhancement and kinetic profiles compared to untreated β-gal-deficient controls. This study establishes an enzyme-activated, protein-binding MR imaging strategy for real-time, noninvasive monitoring of AAV gene therapy.


  • Open Access

    Identification of Non-Competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-Opioid Therapeutic Strategy for Neuropathic Pain

    by Christopher Cioffi, Tanmay Pati, Irina Lotsaris, Srinivasan Jayakumar, Julian Peiser-Oliver, Gaddam Mahesh, Ryan Cantwell Chater, Aravindan Jayaraman, Zachary Frangos, Krishna Suleria, et al.

    Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2-/-) mice. To address these challenges, we developed a series of sec-generation, conformationally restricted indoline analogues that act as non-competitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, non-opioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.

  • Synthetic and medicinal applications of imidazoline scaffolds

    by J.J. Tepe, M. Peddibhotla, T.A. Lansdell, V. Sharma, S. Jayakumar